- Home
- NPCT vs FHTX Comparison
NPCT vs FHTX Comparison
Compare NPCT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- FHTX
- Stock Information
- Founded
- NPCT 2020
- FHTX 2015
- Country
- NPCT United States
- FHTX United States
- Employees
- NPCT N/A
- FHTX N/A
- Industry
- NPCT Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NPCT Finance
- FHTX Health Care
- Exchange
- NPCT Nasdaq
- FHTX Nasdaq
- Market Cap
- NPCT 340.7M
- FHTX 517.9M
- IPO Year
- NPCT N/A
- FHTX 2020
- Fundamental
- Price
- NPCT $11.34
- FHTX $7.55
- Analyst Decision
- NPCT
- FHTX Strong Buy
- Analyst Count
- NPCT 0
- FHTX 5
- Target Price
- NPCT N/A
- FHTX $16.00
- AVG Volume (30 Days)
- NPCT 107.1K
- FHTX 135.3K
- Earning Date
- NPCT 01-01-0001
- FHTX 11-04-2024
- Dividend Yield
- NPCT 9.82%
- FHTX N/A
- EPS Growth
- NPCT N/A
- FHTX N/A
- EPS
- NPCT N/A
- FHTX N/A
- Revenue
- NPCT N/A
- FHTX $35,185,000.00
- Revenue This Year
- NPCT N/A
- FHTX N/A
- Revenue Next Year
- NPCT N/A
- FHTX $15.40
- P/E Ratio
- NPCT N/A
- FHTX N/A
- Revenue Growth
- NPCT N/A
- FHTX 61.95
- 52 Week Low
- NPCT $8.58
- FHTX $2.70
- 52 Week High
- NPCT $10.63
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NPCT 31.22
- FHTX 45.26
- Support Level
- NPCT $11.46
- FHTX $7.24
- Resistance Level
- NPCT $11.55
- FHTX $8.35
- Average True Range (ATR)
- NPCT 0.15
- FHTX 0.54
- MACD
- NPCT -0.05
- FHTX -0.06
- Stochastic Oscillator
- NPCT 9.68
- FHTX 43.20
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.